Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC

Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC

Submitted by admin on June 3, 2019 - 11:29am
Source: 
Pharmaceutical Business Review
News Tags: 
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Headline: 
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
snippet: 

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Do Not Allow Advertisers to Use My Personal information